CLDF Title
Home | Contact Us | Bookmark
HEPATITIS
HBV HCV HDV
CLD HEALTH OUTCOMES
CIRRHOSIS
CIRRHOSIS HEPATIC ENCEPHALOPATHY (HE) HEPATORENAL SYNDROME (HRS) THROMBOCYTOPENIA
NASH
CHOLESTATIC
PRIMARY BILIARY CHOLANGITIS (PBC)
HCC ALCOHOL LIVER DISEASE PEDIATRIC LIVER DISEASE
About CLDF
Board of Trustees Board of Advisors/Faculty CLDF Committees 2022 GI Fellow Board of Advisors
Embassy of Education  
Slide Library Webcasts Abstract Library
 
HDV-Single Disease Content  
Featured Article

Dynamic CME Resource Library
     
Prevalence of Hepatitis B and Hepatitis D Virus Infections in the United States, 2011-2016   Publication
Webcasts
     
Hepatitis B and D Infection   Educational Webcast
HBV/HDV Hot Topics & Virtual Roundtable   Educational Webcast
HBV, HCV, and HDV   Educational Webcast
Recognizing Hepatitis D (HDV): Epidemiology, Virology, Tests and Treatment Options   Educational Webcast
Slide Library
   Released: 2022
test
Recognizing Hepatitis D (HDV): Epidemiology, Virology, Tests and Treatment Options
67 slides
 
 
   Released: 2019
test
Hepatitis Delta Virus (HDV)
35 slides
 
 
 
 
 
 
Abstract Library
1.Emerging anti-HDV drugs and HBV cure strategies with anti-HDV activity
 

Liver Int. 2023 Apr 5. doi: 10.1111/liv.15417. Online ahead of print.

Armando A Roca Suarez 1 2, Enkhtuul Batbold 3, Birke Bartosch 1 2, Naranjargal Dashdorj 3 4, Barbara Testoni 1 2, Fabien Zoulim 1 2 5
 
2.Molecular and Clinical Features of Hepatocellular Carcinoma in Patients with HBV-HDV Infection
 

J Hepatocell Carcinoma. 2023 Apr 25;10:713-724. doi: 10.2147/JHC.S384751.eCollection 2023.

Federico Costante # 1, Leonardo Stella # 1, Francesco Santopaolo 1 2, Antonio Gasbarrini 1 2, Maurizio Pompili 1 2, Tarik Asselah # 3, Francesca Romana Ponziani 1 2
 
3.Strain-specific responsiveness of hepatitis D virus to interferon-alpha treatment
 

JHEP Rep. 2023 Jan 24;5(4):100673. doi: 10.1016/j.jhepr.2023.100673. eCollection 2023 Apr.

Katja Giersch 1, Paulina Perez-Gonzalez 1, Lennart Hendricks 1, Nora Goldmann 2, Jonathan Kolbe 1, Lennart Hermanussen 1, Jan-Hendrick Bockmann 1 3, Tassilo Volz 1, Annika Volmari 1, Lena Allweiss 1 3, Joerg Petersen 4, Dieter Glebe 2 3, Marc Lütgehetmann 3 5, Maura Dandri 1 3
 
4.No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta
 

J Hepatol. 2023 Apr 27;S0168-8278(23)00313-6. doi: 10.1016/j.jhep.2023.04.027.Online ahead of print.

Julius Hollnberger 1, Yang Liu 2, Simin Xu 3, Silvia Chang 3, Ross Martin 3, Savrina Manhas 3, Thomas Aeschbacher 3, Bin Han 3, Tahmineh Yazdi 3, Lindsey May 3, Dong Han 3, Alex Shornikov 3, John Flaherty 3, Dmitry Manuilov 3, Vithika Suri 3, Tarik Asselah 4, Pietro Lampertico 5, Heiner Wedemeyer 6, Soo Aleman 7, Christopher Richards 3, Roberto Mateo 3, Evguenia Maiorova 3, Tomas Cihlar 3, Hongmei Mo 3, Stephan Urban 8
 
5.Silent HDV epidemics culminates in high levels of liver cirrhosis in endemic region despite 20 years of HBV vaccination
 

J Viral Hepat. 2023 Mar;30(3):182-194. doi: 10.1111/jvh.13783. Epub 2022 Dec 27.

Olga V Isaeva 1 2, Karen K Kyuregyan 1 2 3, Anastasia A Karlsen 1 2 3, Oleg V Kuzmin 2, Ilya A Potemkin 1 2, Vera S Kichatova 1 2, Fedor A Asadi Mobarkhan 2, Eugeniy V Mullin 2, Tatyana V Kozhanova 4 5, Victor A Manuylov 6, Andrey A Pochtovyy 6, Vladimir A Gushchin 6, Anna A Saryglar 7, Lyudmila Yu Ilchenko 2 4, Mikhail I Mikhailov 1 2
 
6.Hepatitis D virus infection: Progress on the path toward disease control and cure
 

J Viral Hepat. 2023 Mar 1. doi: 10.1111/jvh.13825. Online ahead of print.  Mark S Sulkowski 1
 
7.Hepatitis B virus and hepatitis D virus infection in women with or at risk for HIV infection in the United States
 

Front Med (Lausanne). 2023 Mar 2;10:1070420. doi: 10.3389/fmed.2023.1070420.eCollection 2023.

Ilona Argirion 1, Parag Mahale 1, Ruth M Pfeiffer 2, Ping Liu 3, Adaora A Adimora 4, Matthew J Akiyama 5 6, Hector H Bolivar 7, Audrey French 8 9, Michael Plankey 10, Jennifer C Price 11, Aadia Rana 12, Anandi Sheth 13 14, Jill Koshiol 1, Eric C Seaberg 15, Mark H Kuniholm 16, Jeffrey Glenn 3, Thomas R O'Brien 1
 
8.Treating hepatitis D with bulevirtide - Real-world experience from 114 patients
 

JHEP Rep. 2023 Mar 15;5(4):100686. doi: 10.1016/j.jhepr.2023.100686. eCollection 2023 Apr.

Christopher Dietz-Fricke 1, Frank Tacke 2, Caroline Zöllner 2, Münevver Demir 2, Hartmut H Schmidt 3, Christoph Schramm 3, Katharina Willuweit 3, Christian M Lange 4, Sabine Weber 4, Gerald Denk 4, Christoph P Berg 5, Julia M Grottenthaler 5, Uta Merle 6, Alexander Olkus 6, Stefan Zeuzem 7, Kathrin Sprinzl 7, Thomas Berg 8, Florian van Bömmel 8, Johannes Wiegand 8, Toni Herta 8, Thomas Seufferlein 9, Eugen Zizer 9, Nektarios Dikopoulos 9, Robert Thimme 10, Christoph Neumann-Haefelin 10, Peter R Galle 11, Martin Sprinzl 11, Ansgar W Lohse 12, Julian Schulze Zur Wiesch 12 13, Jan Kempski 12 14, Andreas Geier 15, Florian P Reiter 15, Bernhard Schlevogt 16, Juliana Gödiker 16, Wolf Peter Hofmann 17, Peter Buggisch 18, Julia Kahlhöfer 1, Kerstin Port 1, Benjamin Maasoumy 1, Markus Cornberg 1 19 20, Heiner Wedemeyer 1 21 22 19, Katja Deterding 1
 
9.Bulevirtide-based treatment strategies for chronic hepatitis delta: A review
 

J Viral Hepat. 2023 Feb 5. doi: 10.1111/jvh.13811. Online ahead of print.

Elisabetta Degasperi 1, Maria Paola Anolli 1, Pietro Lampertico 1 2
 
10.Treatment of chronic hepatitis d with peginterferon lambda - the phase 2 LIMT-1 clinical trial
 

Hepatology. 2023 Feb 20. doi: 10.1097/HEP.0000000000000309. Online ahead of print.

Ohad Etzion 1 2, Saeed Hamid 3, Yoav Lurie 4, E J Gane 5, David Yardeni 1 2, Sarah Duehren 6, N Bader 3, Anat Nevo-Shor 1 2, S M Channa 7, S J Cotler 6, M Mawani 3, Om Parkash 3, Harel Dahari 6, Choong Ingrid 8, Jeffrey Glenn 9
 
11.Kinetics and predictive value of HBcrAg, HBV RNA and anti-HBc during bulevirtide treatment of chronic HDV-infected patients
 

J Viral Hepat. 2023 Jan 17. doi: 10.1111/jvh.13804. Online ahead of print.

Lisa Sandmann 1 2, Katja Deterding 1, Birgit Bremer 1, Kerstin Port 1, Markus Cornberg 1 2 3 4, Heiner Wedemeyer 1 2 3, Benjamin Maasoumy 1 3
 
12.Delta hepatitis epidemiology and the global burden of disease
 

Viral Hepat. 2023 Jan 10. doi: 10.1111/jvh.13797. Online ahead of print.

Tatyana Kushner 1
 
13.Diagnosis of HDV: From virology to non-invasive markers of fibrosis
 

Liver Int. 2023 Jan 9. doi: 10.1111/liv.15515. Online ahead of print.

Nehna Abdul Majeed 1, Asif A Hitawala 1, Theo Heller 1, Christopher Koh 1
 
14.Hepatitis D virus interferes with hepatitis B virus RNA production via interferon-dependent and -independent mechanisms
 

J Hepatol. 2023 Jan 23;S0168-8278(23)00016-8. doi: 10.1016/j.jhep.2023.01.005.Online ahead of print.

Julie Lucifora 1, Dulce Alfaiate 2, Caroline Pons 3, Maud Michelet 4, Ricardo Ramirez 5, Floriane Fusil 6, Fouzia Amirache 6, Axel Rossi 7, Anne-Flore Legrand 6, Emilie Charles 6, Serena Vegna 4, Rayan Farhat 4, Michel Rivoire 8, Guillaume Passot 9, Nicolas Gadot 4, Barbara Testoni 4, Charlotte Bach 10, Thomas F Baumert 11, Anastasia Hyrina 5, Rudolf K Beran 5, Fabien Zoulim 12, Andre Boonstra 13, Hildegard Büning 7, Eloi R Verrier 10, François-Loïc Cosset 6, Simon P Fletcher 5, Anna Salvetti 6, David Durantel 3
 
15.Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy
 

Drug Des Devel Ther. 2023 Jan 21;17:155-166. doi: 10.2147/DDDT.S379964.eCollection 2023.

Vicente Soriano 1, Victor Moreno-Torres 1 2, Ana Treviño 1, Octavio Corral 1, Carmen de Mendoza 2
 
16.Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension
 

J Hepatol. 2022 Dec;77(6):1525-1531. doi: 10.1016/j.jhep.2022.07.016. Epub 2022 Aug 13.

Elisabetta Degasperi 1, Maria Paola Anolli 1, Sara Colonia Uceda Renteria 2, Dana Sambarino 1, Marta Borghi 1, Riccardo Perbellini 1, Caroline Scholtes 3, Floriana Facchetti 1, Alessandro Loglio 1, Sara Monico 1, Mirella Fraquelli 4, Andrea Costantino 4, Ferruccio Ceriotti 2, Fabien Zoulim 3, Pietro Lampertico 5
 
17.Beyond bulevirtide: Alternative therapeutic options for the management of hepatitis delta virus
 

J Viral Hepat. 2022 Dec 18. doi: 10.1111/jvh.13789. Online ahead of print.

Tarik Asselah 1
 
18.The Delta Delta: Gaps in screening and patient assessment for hepatitis D virus infection
 

J Viral Hepat. 2022 Dec 2. doi: 10.1111/jvh.13779. Online ahead of print.

Rohit Nathani 1, Randy Leibowitz 1, Dewan Giri 2, Carolina Villarroel 2, Sidra Salman 1, Mantej Sehmbhi 1, Bo Hyung Yoon 3, Amreen Dinani 4, Ilan Weisberg 5
 
19.Hepatitis B and Hepatitis D Viruses: A Comprehensive Update with an Immunological Focus
 

Int J Mol Sci. 2022 Dec 15;23(24):15973. doi: 10.3390/ijms232415973.

Daniel G Sausen 1, Oren Shechter 1, William Bietsch 2, Zhenzhen Shi 2, Samantha M Miller 3, Elisa S Gallo 4, Harel Dahari 2, Ronen Borenstein 2
 
20.Epidemiology, presentation, and therapeutic approaches for hepatitis D infections
 

Expert Rev Anti Infect Ther. 2022 Dec 28;1-16. doi: 10.1080/14787210.2023.2159379.Online ahead of print.

Hanna Blaney 1, Mian Khalid 1, Theo Heller 2, Christopher Koh 2
 
21.Hepatitis delta virus: Disease assessment and stratification
 

J Viral Hepat. 2022 Dec 2. doi: 10.1111/jvh.13777. Online ahead of print.

Apostolos Koffas 1, Lung-Yi Mak 1 2, Patrick T F Kennedy 1
 
22.The immune landscape in Hepatitis Delta Virus Infection - still an open field!
 

 Viral Hepat. 2022 Dec 18. doi: 10.1111/jvh.13785. Online ahead of print.

Upkar S Gill 1
 
23.Treatment of Chronic Hepatitis D with Bulevirtide-A Fight against Two Foes-An Update
 

Cells. 2022 Nov 8;11(22):3531. doi: 10.3390/cells11223531.

Peter Ferenci 1, Thomas Reiberger 1, Mathias Jachs 1
 
24.Hepatitis D virus: Improving virological knowledge to develop new treatments
 

Antiviral Res. 2022 Nov 14;105461. doi: 10.1016/j.antiviral.2022.105461.Online ahead of print.

Khalfi Pierre 1, Majzoub Karim 2, Patrick T Kennedy 3, Asselah Tarik 4
 
25.Chronic Hepatitis B Virus and Hepatitis D Virus: New Developments
 

Clin Liver Dis. 2023 Feb;27(1):17-25. doi: 10.1016/j.cld.2022.08.001.Epub 2022 Oct 18.

Ann Robinson 1, Robert Wong 2, Robert G Gish 3
 
26.Hepatitis D virus infection in a large cohort of immigrants in southern Italy: a multicenter, prospective study
 

Infection. 2022 Oct 12;1-8. doi: 10.1007/s15010-022-01938-0. Online ahead of print.

Pisaturo Mariantonietta 1 2, Alessio Loredana 1 3, Di Fraia Alessandra 1, Macera Margherita 1 4, Minichini Carmine 1, Cordua Emanuele 1, Onorato Lorenzo 1 5, Scotto Gaetano 6 7, Di Caprio Giovanni 2 8, Calò Federica 1 4, Sagnelli Caterina 1 5, Coppola Nicola 9
 
27.Natural history of untreated HDV patients: always a progressive disease?
 

Liver Int. 2022 Oct 28. doi: 10.1111/liv.15467. Online ahead of print.

Habiba Kamal 1 2, Soo Aleman 1 2 3
 
28.Novel concepts on mechanisms underlying Hepatitis Delta virus persistence and related pathogenesis
 

J Viral Hepat. 2022 Oct 18. doi: 10.1111/jvh.13755. Online ahead of print.

Romina Salpini 1, Stefano D'Anna 1, Lorenzo Piermatteo 1 2, Valentina Svicher 1 2
 
29.Liver Transplantation in Hepatitis B/Hepatitis D (Delta) Virus Coinfected Recipients
 

Transplantation. 2022 Oct 1;106(10):1935-1939.doi: 10.1097/TP.0000000000004138. Epub 2022 Apr 11.

Silvia Martini 1, Francesco Tandoi 2, Renato Romagnoli 2, Mario Rizzetto 1
 
30.Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial
 

Lancet Infect Dis. 2022 Sep 13;S1473-3099(22)00318-8. doi: 10.1016/S1473-3099(22)00318-8.Online ahead of print.

Heiner Wedemeyer 1, Katrin Schöneweis 2, Pavel Bogomolov 3, Antje Blank 4, Natalia Voronkova 5, Tatiana Stepanova 6, Olga Sagalova 7, Vladimir Chulanov 8, Marina Osipenko 9, Viacheslav Morozov 10, Natalia Geyvandova 11, Snezhana Sleptsova 12, Igor G Bakulin 13, Ilsiyar Khaertynova 14, Marina Rusanova 15, Anita Pathil 16, Uta Merle 17, Birgit Bremer 18, Lena Allweiss 19, Florian A Lempp 20, Kerstin Port 18, Mathias Haag 21, Matthias Schwab 22, Julian Schulze Zur Wiesch 19, Markus Cornberg 18, Walter E Haefeli 4, Maura Dandri 19, Alexander Alexandrov 23, Stephan Urban 24
 
31.Medical Advances in Hepatitis D Therapy: Molecular Targets
 

Int J Mol Sci. 2022 Sep 16;23(18):10817. doi: 10.3390/ijms231810817.

Amelie Vogt 1, Sabrina Wohlfart 1, Stephan Urban 2, Walter Mier 1
 
32.Immunology of hepatitis D virus infection: general concepts and present evidence
 

Liver Int. 2022 Sep 8. doi: 10.1111/liv.15424. Online ahead of print.

Reem Hoblos 1, Helenie Kefalakes 1
 
33.Hepatitis D virus-induced interferon response and administered interferons control cell division-mediated virus spread
 

J Hepatol. 2022 Oct;77(4):957-966. doi: 10.1016/j.jhep.2022.05.023. Epub 2022 May 28.

Zhenfeng Zhang 1, Yi Ni 1, Florian A Lempp 1, Lisa Walter 1, Pascal Mutz 2, Ralf Bartenschlager 3, Stephan Urban 4
 
34.Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections
 

Gut. 2022 Aug 17;gutjnl-2022-327216. doi: 10.1136/gutjnl-2022-327216. Online ahead of print.

Rani Burm 1, Panagiota Maravelia 2, Gustaf Ahlen 2, Sandra Ciesek 3 4 5, Noelia Caro Perez 2, Anna Pasetto 2, Stephan Urban 6, Freya Van Houtte 1, Lieven Verhoye 1, Heiner Wedemeyer 7, Magnus Johansson 8, Lars Frelin 2, Matti Sällberg 9, Philip Meuleman 10
 
35.Hepatitis D virus (HDV): investigational therapeutic agents in clinical trials
 

Expert Opin Investig Drugs. 2022 Sep;31(9):905-920.doi: 10.1080/13543784.2021.1977795. Epub 2021 Oct 1.

Bilal Asif 1, Christopher Koh 2
 
36.Low Performance of Hepatitis Delta Virus Testing Among Two National Cohorts of Chronic Hepatitis B Patients in the United States
 

Am J Gastroenterol. 2022 Aug 12. doi: 10.14309/ajg.0000000000001947. Online ahead of print.

Robert J Wong 1 2, Harvey W Kaufman 3, Justin K Niles 3, Cheng Chen 4, Zeyuan Yang 2, Hema Kapoor 3, Ramsey Cheung 1 2, Robert G Gish 5
 
37.Bulevirtide for patients with compensated chronic hepatitis delta: A review
 

Liver Int. 2022 Aug 9. doi: 10.1111/liv.15389. Online ahead of print.

Elisabetta Degasperi 1, Maria P Anolli 1, Pietro Lampertico 1 2
 
38.Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis D
 

JHEP Rep. 2022 Jul 21;4(10):100547. doi: 10.1016/j.jhepr.2022.100547. eCollection 2022 Oct.

Adriana Palom 1 2, Ariadna Rando-Segura 3, Judit Vico 1, Beatriz Pacín 3 4, Elena Vargas 1 2, Ana Barreira-Díaz 1 2 5, Francisco Rodríguez-Frías 3 4 5, Mar Riveiro-Barciela 1 2 5, Rafael Esteban 1 2 5, Maria Buti 1 2 5
 
39.Clinical Trials in HDV: Measuring Success
 

Hepatology. 2022 Aug 15. doi: 10.1002/hep.32732. Online ahead of print.

Ben L Da 1
 
40.A Review of HDV Infection
 

Viruses. 2022 Aug 10;14(8):1749. doi: 10.3390/v14081749.

Gian Paolo Caviglia 1, Alessia Ciancio 1 2, Mario Rizzetto 1
 
41.Interferon-based treatment of chronic hepatitis D
 

Liver Int. 2022 Aug 24. doi: 10.1111/liv.15410. Online ahead of print.

Lisa Sandmann 1 2 3 4, Heiner Wedemeyer 1 2 3 5
 
42.Hepatitis D (DELTA)
 

New Microbiol. 2022 Jul;45(3):149-154.

Mario Rizzetto 1
 
43.Treatment of hepatitis delta and HIV infection
 

Liver Int. 2022 Jun 24.doi: 10.1111/liv.15345. Online ahead of print.

Vicente Soriano 1, Carmen de Mendoza 2, Ana Treviño 1, José Manuel Ramos-Rincón 3, Víctor Moreno-Torres 2, Octavio Corral 1, Pablo Barreiro 4
 
44.BULEVIRTIDE WITH OR WITHOUT PEGIFNa FOR PATIENTS WITH COMPENSATED CHRONIC HEPATITIS DELTA: FROM CLINICAL TRIALS TO REAL LIFE STUDIES
 

J Hepatol. 2022 Jun 22;S0168-8278(22)00373-7. doi: 10.1016/j.jhep.2022.06.010.Online ahead of print.

Pietro Lampertico 1, Dominique Roulot 2, Heiner Wedemeyer 3
 
45.Recent breakthroughs in the treatment of chronic hepatitis Delta
 

Infez Med. 2022 Jun 1;30(2):204-210. doi: 10.53854/liim-3002-5. eCollection 2022.

Giuseppina Brancaccio 1, Laura Gaeta 2, Alessandro Vitale 3, Giovanni B Gaeta 4
 
46.Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-Results of A "real world" Study
 

Aliment Pharmacol Ther. 2022 May 5. doi: 10.1111/apt.16945. Online ahead of print.

Mathias Jachs 1 2, Caroline Schwarz 3, Marlene Panzer 4, Teresa Binter 1 2, Stephan W Aberle 5, Lukas Hartl 1 2, Kristina Dax 6, Elmar Aigner 7, Albert F Stättermayer 1 2, Petra Munda 1, Ivo Graziadei 8, Heidemarie Holzmann 5, Michael Trauner 1 2, Heinz Zoller 4, Michael Gschwantler 3, Mattias Mandorfer 1 2, Thomas Reiberger 1 2, Peter Ferenci 1
 
47.COVID-19 vaccine acceptability among people in Australia who inject drugs: Update from the 2021 Illicit Drug Reporting System interviews
 

Drug Alcohol Rev. 2022 Feb 20;10.1111/dar.13448. doi: 10.1111/dar.13448. Online ahead of print.

Olivia Price 1, Paul M Dietze 1 2 3 4, Lisa Maher 5, Sione Crawford 6, Amy Peacock 1 7
 
48.Hepatitis D virus dual infection increased the risk of hepatocellular carcinoma compared with hepatitis B virus mono infection: A meta-analysis
 

 Chin Med Assoc. 2022 Jan 1;85(1):30-41.doi: 10.1097/JCMA.0000000000000606.

Tien-En Chang 1 2 3, Chien-Wei Su 1 2 4, Yi-Shin Huang 1 2, Yi-Hsiang Huang 1 5, Ming-Chih Hou 1 2, Jaw-Ching Wu 6 5 7
 
49.Liver Transplantation in Hepatitis B/Hepatitis D (Delta) Virus Coinfected Recipients
 

Transplantation. 2022 Apr 11. doi: 10.1097/TP.0000000000004138. Online ahead of print.

Silvia Martini 1, Francesco Tandoi 2, Renato Romagnoli 2, Mario Rizzetto 1
 
50.Therapeutic Advances in Viral Hepatitis A-E
 

Adv Ther. 2022 Apr;39(4):1524-1552. doi: 10.1007/s12325-022-02070-z.Epub 2022 Feb 27.

Navroop Nagra 1, Richard A Kozarek 2, Blaire E Burman 3
 
51.Clinical Application of Droplet Digital PCR for Hepatitis Delta Virus Quantification
 

Biomedicines. 2022 Mar 29;10(4):792. doi: 10.3390/biomedicines10040792.

Antonella Olivero 1 2, Chiara Rosso 1, Alessia Ciancio 1 2, Maria Lorena Abate 1 2, Aurora Nicolosi 1, Giulia Troshina 1, Angelo Armandi 1, Davide Giuseppe Ribaldone 1 2, Giorgio Maria Saracco 1 2, Elisabetta Bugianesi 1 2, Mario Rizzetto 1, Gian Paolo Caviglia 1
 
52.Therapy of Chronic Viral Hepatitis: The Light at the End of the Tunnel?
 

Biomedicines. 2022 Feb 24;10(3):534. doi: 10.3390/biomedicines10030534.

Giorgio Maria Saracco 1, Alfredo Marzano 1, Mario Rizzetto 1
 
53.Combination of Novel Therapies for HDV
 

Viruses. 2022 Jan 28;14(2):268. doi: 10.3390/v14020268.

Menashe Elazar 1, Jeffrey S Glenn 1 2
 
54.Management of Delta Hepatitis 45 Years after the Discovery of HDV
 

J Clin Med. 2022 Mar 13;11(6):1587. doi: 10.3390/jcm11061587.

Stefano Brillanti 1
 
55.Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis
 

United European Gastroenterol J. 2021 Dec;9(10):1119-1127.doi: 10.1002/ueg2.12163. Epub 2021 Dec 7.

Mathias Jachs 1 2, Teresa Binter 1 2, Caroline Schmidbauer 2 3, Lukas Hartl 1 2, Michael Strasser 4, Hermann Laferl 5, Stephanie Hametner-Schreil 6, Alexander Lindorfer 6, Kristina Dax 7, Rudolf E Stauber 8, Harald H Kessler 9, Sebastian Bernhofer 10, Andreas Maieron 10, Lorin Loacker 11, Simona Bota 12, Isabel Santonja 13, Petra Munda 1, Mattias Mandorfer 1 2, Markus Peck-Radosavljevic 12, Heidemarie Holzmann 13, Michael Gschwantler 2 3, Heinz Zoller 14, Peter Ferenci 1, Thomas Reiberger 1 2
 
56.Combination of Novel Therapies for HDV
 

Viruses. 2022 Jan 28;14(2):268. doi: 10.3390/v14020268.

Menashe Elazar 1, Jeffrey S Glenn 1 2
 
57.Management of Delta Hepatitis 45 Years after the Discovery of HDV
 

J Clin Med. 2022 Mar 13;11(6):1587. doi: 10.3390/jcm11061587.

Stefano Brillanti 1
 
58.Hepatitis D virus (HDV) prevalence in Austria is low but causes considerable morbidity due to fast progression to cirrhosis
 

United European Gastroenterol J. 2021 Dec;9(10):1119-1127.doi: 10.1002/ueg2.12163. Epub 2021 Dec 7.

Mathias Jachs 1 2, Teresa Binter 1 2, Caroline Schmidbauer 2 3, Lukas Hartl 1 2, Michael Strasser 4, Hermann Laferl 5, Stephanie Hametner-Schreil 6, Alexander Lindorfer 6, Kristina Dax 7, Rudolf E Stauber 8, Harald H Kessler 9, Sebastian Bernhofer 10, Andreas Maieron 10, Lorin Loacker 11, Simona Bota 12, Isabel Santonja 13, Petra Munda 1, Mattias Mandorfer 1 2, Markus Peck-Radosavljevic 12, Heidemarie Holzmann 13, Michael Gschwantler 2 3, Heinz Zoller 14, Peter Ferenci 1, Thomas Reiberger 1 2
 
59.Review article: emerging insights into the immunopathology, clinical and therapeutic aspects of hepatitis delta virus
 

Aliment Pharmacol Ther. 2022 Mar 16. doi: 10.1111/apt.16807. Online ahead of print.

Carla Usai 1, Upkar S Gill 1 2, Anna C Riddell 3, Tarik Asselah 4 5, Patrick T Kennedy 1 2
 
60.Liver Transplantation for Hepatitis D Virus in the United States: A UNOS Study on Outcomes in the MELD Era
 

Transplant Direct. 2021 Dec 17;8(1):e1253. doi: 10.1097/TXD.0000000000001253.eCollection 2022 Jan.

Tatyana Kushner 1, Ben L Da 2, Aryana Chan 1, Douglas Dieterich 1, Keith Sigel 3, Behnam Saberi 1 4
 
61.Comprehensive Analysis of Hepatitis Delta Virus Assembly Determinants According to Genotypes: Lessons From a Study of 526 Hepatitis Delta Virus Clinical Strains
 

Front Microbiol. 2021 Nov 16;12:751531. doi: 10.3389/fmicb.2021.751531. eCollection 2021.

Athenaïs Gerber 1 2, Frédéric Le Gal 1 2 3, Samira Dziri 1 2, Chakib Alloui 1 2 3, Dominique Roulot 2 3 4, Paul Dény 1 5, Camille Sureau 6, Ségolène Brichler 1 2 3, Emmanuel Gordien 1 2 3
 
62.Hepatitis Delta Virus Genome RNA Synthesis Initiates at Position 1646 with a Nontemplated Guanosine
 

J Virol. 2022 Feb 23;96(4):e0201721. doi: 10.1128/JVI.02017-21. Epub 2021 Dec 8.

Susannah Stephenson-Tsoris 1, John L Casey 1
 
63.Hepatitis B virus/hepatitis D virus epidemiology: Changes over time and possible future influence of the SARS-CoV-2 pandemic
 

World J Gastroenterol. 2021 Nov 14;27(42):7271-7284.doi: 10.3748/wjg.v27.i42.7271.

Caterina Sagnelli 1, Mariantonietta Pisaturo 2, Caterina Curatolo 2, Alessio Vinicio Codella 2, Nicola Coppola 2, Evangelista Sagnelli 3
 
64.A Rapid Point-of-Care Test for the Serodiagnosis of Hepatitis Delta Virus Infection
 

Viruses. 2021 Nov 26;13(12):2371. doi: 10.3390/v13122371.

Florian A Lempp 1 2, Imme Roggenbach 1, Shirin Nkongolo 1 2 3, Volkan Sakin 1, Franziska Schlund 1, Paul Schnitzler 4, Heiner Wedemeyer 5, Frédéric Le Gal 6, Emmanuel Gordien 6, Cihan Yurdaydin 7 8, Stephan Urban 1 2
 
65.Novel Therapies of Hepatitis B and D
 

Microorganisms. 2021 Dec 17;9(12):2607. doi: 10.3390/microorganisms9122607.

Iman Waheed Khan 1, Mati Ullah Dad Ullah 1, Mina Choudhry 1, Mukarram Jamat Ali 1, Muhammad Ashar Ali 1, Sam L K Lam 2, Pir Ahmad Shah 3, Satinder Pal Kaur 1, Daryl T Y Lau 1
 
66.Liver Transplantation for Hepatitis D Virus in the United States: A UNOS Study on Outcomes in the MELD Era
 

Transplant Direct. 2021 Dec 17;8(1):e1253. doi: 10.1097/TXD.0000000000001253.eCollection 2022 Jan.

Tatyana Kushner 1, Ben L Da 2, Aryana Chan 1, Douglas Dieterich 1, Keith Sigel 3, Behnam Saberi 1 4
 
67.Hepatitis D-associated hospitalizations in the United States: 2010-2018
 

J Viral Hepat. 2022 Jan 25. doi: 10.1111/jvh.13645. Online ahead of print.

Paul Wasuwanich 1, Catherine W Striley 2, Saleem Kamili 3, Eyasu H Teshale 3, Eric C Seaberg 4, Wikrom Karnsakul 5
 
68.Chronic hepatitis D - What is changing?
 

J Viral Hepat. 2022 Feb 4. doi: 10.1111/jvh.13651. Online ahead of print.

David Yardeni 1, Theo Heller 1, Christopher Koh 1
 
69.Viral hepatitis in 2021: The challenges remaining and how we should tackle them
 

World J Gastroenterol. 2022 Jan 7;28(1):76-95. doi: 10.3748/wjg.v28.i1.76.

Rebecca Dunn 1, Aaron Wetten 2, Stuart McPherson 2, Mhairi C Donnelly 3
 
70.The global hepatitis delta virus (HDV) epidemic: what gaps to address in order to mount a public health response?
 

Arch Public Health. 2021 Oct 19;79(1):180. doi: 10.1186/s13690-021-00693-2.

Tomoyuki Hayashi 1 2, Yumie Takeshita 3 4, Yvan J-F Hutin 3, Hande Harmanci 3, Philippa Easterbrook 3, Sarah Hess 3, Judith van Holten 3, Ena Oghenekaro Oru 3, Shuichi Kaneko 4, Cihan Yurdaydin 5 6, Marc Bulterys 3
 
71.Acute Delta Hepatitis in Italy spanning three decades (1991-2019): Evidence for the effectiveness of the hepatitis B vaccination campaign
 

J Viral Hepat. 2022 Jan;29(1):78-86. doi: 10.1111/jvh.13620. Epub 2021 Oct 7.

Tommaso Stroffolini 1, Filomena Morisco 2, Luigina Ferrigno 3, Giuseppina Pontillo 2, Giuseppina Iantosca 3, Valentina Cossiga 2, Simonetta Crateri 3, Maria Elena Tosti 3, SEIEVA collaborating group

 
 
72.Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease
 

Gut. 2021 Sep;70(9):1782-1794. doi: 10.1136/gutjnl-2020-323888. Epub 2021 Jun 8.

Stephan Urban # 1 2, Christoph Neumann-Haefelin # 3, Pietro Lampertico 4 5
 
73.Hepatitis delta in patients hospitalized in Spain (1997-2018)
 

AIDS. 2021 Nov 15;35(14):2311-2318.doi: 10.1097/QAD.0000000000003024.

José-Manuel Ramos-Rincon 1, Héctor Pinargote 1, Clara Ramos-Belinchón 2, Carmen de Mendoza 3, Antonio Aguilera 4, Vicente Soriano 5
 
74.The hepatitis D virus in Italy. A vanishing infection, not yet a vanished disease
 

J Adv Res. 2021 Mar 2;33:183-187. doi: 10.1016/j.jare.2021.02.009. eCollection 2021 Nov.

Gian Paolo Caviglia 1, Silvia Martini 2, Alessia Ciancio 1 2, Grazia Anna Niro 3, Antonella Olivero 1, Rossana Fontana 3, Francesco Tandoi 4, Chiara Rosso 1, Renato Romagnoli 4 5, Giorgio Maria Saracco 1 2, Antonina Smedile 1 2, Mario Rizzetto 1 2
 
75.Hepatitis D Review: Challenges for the Resource-Poor Setting
 

Viruses. 2021 Sep 23;13(10):1912. doi: 10.3390/v13101912.

Alice U Lee 1 2, Caroline Lee 3
 
76.A Mathematical Analysis of HDV Genotypes: From Molecules to Cells
 

Mathematics (Basel). 2021 Sep 1;9(17):2063. doi: 10.3390/math9172063. Epub 2021 Aug 26.

Rami Zakh 1, Alexander Churkin 2, Franziska Totzeck 3, Marina Parr 3, Tamir Tuller 4, Ohad Etzion 5, Harel Dahari 6, Michael Roggendorf 7, Dmitrij Frishman 3, Danny Barash 1
 
77.Hepatitis D virus (HDV): Investigational therapeutic agents in clinical trials
 

Expert Opin Investig Drugs. 2021 Sep  doi: 10.1080/13543784.2021.1977795.Online ahead of print.

Bilal Asif 1, Christopher Koh 2
 
78.Variable In Vivo Hepatitis D Virus (HDV) RNA Editing Rates According to the HDV Genotype
 

Viruses. 2021 Aug 9;13(8):1572. doi: 10.3390/v13081572.

Samira Dziri 1, Christophe Rodriguez 2 3, Athenaïs Gerber 1, Ségolène Brichler 1 3, Chakib Alloui 1 3, Dominique Roulot 3 4, Paul Dény 1 5, Jean Michel Pawlotsky 2 3, Emmanuel Gordien 1 3, Frédéric Le Gal 1 3
 
79.Liver-resident bystander CD8 + T cells contribute to liver disease pathogenesis in chronic hepatitis D virus infection
 

Gastroenterology. 2021 Jul 21;S0016-5085(21)03278-9. doi: 10.1053/j.gastro.2021.07.027.Online ahead of print.

Helenie Kefalakes 1, Xylia J Horgan 1, Min Kyung Jung 1, Georgios Amanakis 2, Devika Kapuria 3, Fabian J Bolte 1, David E Kleiner 4, Christopher Koh 3, Theo Heller 5, Barbara Rehermann 6
 
80.Risk of hepatocellular carcinoma in hepatitis B and D virus co-infected patients: A systematic review and meta-analysis of longitudinal studies
 

J Viral Hepat. 2021 Jul 22. doi: 10.1111/jvh.13577. Online ahead of print.

Habiba Kamal 1 2, Romina Fornes 3, Johanna Simin 3, Per Stål 2 4, Ann-Sofi Duberg 5, Nele Brusselaers 3, Soo Aleman 1 2
 
81.Bulevirtide for HBV and HDV infections
 

Drugs Today (Barc). 2021 Jul;57(7):433-448. doi: 10.1358/dot.2021.57.7.3283861

D Yardeni 1, C Koh 2
 
82.Poor clinical and virological outcome of nucleos(t)ide analogue monotherapy in HBV/HDV co-infected patients
 

Medicine (Baltimore). 2021 Jul 16;100(28):e26571. doi: 10.1097/MD.0000000000026571.

Laura Scheller 1, Gudrun Hilgard 1, Olympia Anastasiou 2, Ulf Dittmer 2, Alisan Kahraman 1 3, Heiner Wedemeyer 1 4, Katja Deterding 1 4
 
83.Hepatitis delta virus: From infection to new therapeutic strategies
 

World J Gastroenterol. 2021 Jun 28;27(24):3530-3542.doi: 10.3748/wjg.v27.i24.3530.

Grazia A Niro 1, Arianna Ferro 2, Francesca Cicerchia 2, Isabella Brascugli 2, Marilena Durazzo 3
 
84.Hepatitis Delta Virus (HDV) and Delta-Like Agents: Insights Into Their Origin
 

Front Microbiol. 2021 Jun 21;12:652962. doi: 10.3389/fmicb.2021.652962.eCollection 2021.

Hans J Netter 1 2, Marilou H Barrios 1 3, Margaret Littlejohn 1, Lilly K W Yuen 1
 
85.One-quarter of chronic hepatitis D patients reach HDV-RNA decline or undetectability during the natural course of the disease
 

Aliment Pharmacol Ther. 2021 Jun 28. doi: 10.1111/apt.16485. Online ahead of print.

Adriana Palom 1 2, Sara Sopena 3, Mar Riveiro-Barciela 1 2 4, Angela Carvalho-Gomes 4 5, Antonio Madejón 4 6, Sergio Rodriguez-Tajes 4 7, Luisa Roade 1 2 4, María García-Eliz 5, Javier García-Samaniego 4 6, Sabela Lens 4 7, Marina Berenguer-Hayme 4 5, Francisco Rodríguez-Frías 2 3 4, Helena Hernandez-Évole 5, Ana Isabel Gil-García 4 6, Ana Barreira 1 2 4, Rafael Esteban 1 2 4, Maria Buti 1 2 4
 
86.Prevalence of hepatitis delta virus among chronic hepatitis B carriers in a large tertiary center in the Netherlands
 

J Clin Virol. 2021 Jun 18;141:104870. doi: 10.1016/j.jcv.2021.104870. Online ahead of print.

Boris J B Beudeker 1, Jolanda J C Voermans 2, Corine H GeurtsvanKessel 2, Robert J de Knegt 3, Tamara Kuhlemann 2, Andre Boonstra 3, Annemiek A van der Eijk 2
 
87.HDV-Like Viruses
 

Viruses. 2021 Jun 23;13(7):1207. doi: 10.3390/v13071207.

Jimena Pérez-Vargas 1, Rémi Pereira de Oliveira 1, Stéphanie Jacquet 2, Dominique Pontier 2, François-Loïc Cosset 1, Natalia Freitas 1
 
88.Update on the management and treatment of viral hepatitis
 

World J Gastroenterol. 2021 Jun 21;27(23):3249-3261.doi: 10.3748/wjg.v27.i23.3249.

Patricia Holanda Almeida 1, Celso E L Matielo 1, Lilian A Curvelo 1, Rodrigo A Rocco 1, Guilherme Felga 1, Bianca Della Guardia 1, Yuri L Boteon 1
 
89.Is hepatitis delta underestimated?
 

Liver Int. 2021 Jun;41 Suppl 1:38-44. doi: 10.1111/liv.14833.
 
90.New therapies for hepatitis delta virus infection
 

Liver Int. 2021 Jun;41 Suppl 1:30-37. doi: 10.1111/liv.14838.

Dimitri Loureiro 1 2, Corinne Castelnau 1 2, Issam Tout 1 2, Nathalie Boyer 1 2, Stéphanie Narguet 1 2, Sabrina Menasria Benazzouz 1 2, Zeina Louis 1 3, Nathalie Pons-Kerjean 1 3, Nathalie Giuly 1 2, Patrick Marcellin 1 2, Abdellah Mansouri 1 2, Tarik Asselah 1 2
 
91.Platelet count as a screening tool for compensated cirrhosis in chronic viral hepatitis
 

World J Gastrointest Pathophysiol. 2021 May 22;12(3):40-50. doi: 10.4291/wjgp.v12.i3.40.

Pallavi Surana 1, Julian Hercun 1, Varun Takyar 1, David E Kleiner 2, Theo Heller 1, Christopher Koh 3
 
92.Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease
 

Gut. 2021 Jun 8;gutjnl-2020-323888. doi: 10.1136/gutjnl-2020-323888.Online ahead of print.

Stephan Urban # 1 2, Christoph Neumann-Haefelin # 3, Pietro Lampertico 4 5
 
93.Hepatitis D Virus and Hepatocellular Carcinoma
 

Viruses. 2021 May 4;13(5):830. doi: 10.3390/v13050830.

Patrizia Farci 1, Grazia Anna Niro 2, Fausto Zamboni 3, Giacomo Diaz 4
 
94.Durable virological response and functional cure of chronic hepatitis D after long-term peginterferon therapy
 

Aliment Pharmacol Ther. 2021 May 28. doi: 10.1111/apt.16408. Online ahead of print.

Julian Hercun 1, Grace E Kim 1, Ben L Da 1, Yaron Rotman 1, David E Kleiner 2, Richard Chang 3, Jeffrey S Glenn 4, Jay H Hoofnagle 5, Christopher Koh 1, Theo Heller 1
 
95.Chronic hepatitis D associated with worse patient-reported outcomes than chronic hepatitis B
 

JHEP Rep. 2021 Mar 17;3(3):100280. doi: 10.1016/j.jhepr.2021.100280. eCollection 2021 Jun.

Maria Buti 1 2, Maria Stepanova 3, Adriana Palom 1, Mar Riveiro-Barciela 1 2, Fatema Nader 3, Luisa Roade 1 2, Rafael Esteban 1 2, Zobair Younossi 4 5
 
96.Innate immunity in hepatitis B and D virus infection: consequences for viral persistence, inflammation, and T cell recognition
 

Semin Immunopathol. 2021 May 21. doi: 10.1007/s00281-021-00864-x.Online ahead of print.

Maura Dandri 1 2, Antonio Bertoletti 3 4, Marc Lütgehetmann 5 6
 
97.From hepatitis A to E: A critical review of viral hepatitis
 

World J Gastroenterol. 2021 Apr 28;27(16):1691-1715. doi: 10.3748/wjg.v27.i16.1691.

Daniel Castaneda 1, Adalberto Jose Gonzalez 2, Mohammad Alomari 2, Kanwarpreet Tandon 2, Xaralambos Bobby Zervos 3
 
98.Identification of hepatitis delta superinfection when investigating transaminitis in HIV/HBV coinfection
 

AIDS. 2021 May 10. doi: 10.1097/QAD.0000000000002940. Online ahead of print.

Ali Hamady 1, Graham S Cooke, Lucy Jane Garvey
 
99.HDV Pathogenesis: Unravelling Ariadne's Thread
 

Viruses. 2021 Apr 28;13(5):778. doi: 10.3390/v13050778.

Eirini D Tseligka 1, Sophie Clément 2, Francesco Negro 2 3
 
100.'Double-hit' pegylated interferon-alpha successfully treats Hepatitis B and Hepatitis D co-infection
 

Oxf Med Case Reports. 2020 Oct 23;2020(10):omaa084.doi: 10.1093/omcr/omaa084. eCollection 2020 Oct.

Meha Bhuva 1, Marie Moore 1, Sambit Sen 1
 
101.Current status of hepatitis delta
 

Curr Opin Pharmacol. 2021 Apr 22;58:62-67. doi: 10.1016/j.coph.2021.03.008.Online ahead of print.

Margarita Papatheodoridi 1, George V Papatheodoridis 2
 
102.Experimental Drugs for the Treatment of Hepatitis D
 

J Exp Pharmacol. 2021 Apr 16;13:461-468. doi: 10.2147/JEP.S235550.eCollection 2021.

Lisa Sandmann 1, Markus Cornberg 1 2
 
103.Assembly and infection efficacy of hepatitis B virus surface protein exchanges in eight hepatitis D virus genotype isolates
 

J Hepatol. 2021 Apr 9;S0168-8278(21)00229-4. doi: 10.1016/j.jhep.2021.03.025.Online ahead of print.

Wenshi Wang 1, Florian A Lempp 2, Franziska Schlund 3, Lisa Walter 3, Charlotte Decker 3, Zhenfeng Zhang 3, Yi Ni 2, Stephan Urban 4
 
104.Hepatitis D virus and liver transplantation: Indications and outcomes
 

World J Hepatol. 2021 Mar 27;13(3):291-299. doi: 10.4254/wjh.v13.i3.291.

Haris Muhammad 1, Aniqa Tehreem 2, Muhammad Baraa Hammami 3, Peng-Sheng Ting 3, Ramzan Idilman 4, Ahmet Gurakar 5
 
105.The year's new drugs and biologics 2020
 

Drugs Today (Barc). 2021 Feb;57(2):101-177. doi: 10.1358/dot.2021.57.2.3275929.

A I Graul 1, L A Sorbera 2
 
106.Lonafarnib: First Approval
 

Drugs. 2021 Feb;81(2):283-289. doi: 10.1007/s40265-020-01464-z.

Sohita Dhillon 1
 
107.HBV/HDV Co-Infection: Epidemiological and Clinical Changes, Recent Knowledge and Future Challenges
 

Life (Basel). 2021 Feb 22;11(2):169. doi: 10.3390/life11020169.

Caterina Sagnelli 1, Evangelista Sagnelli 1, Antonio Russo 1, Mariantonietta Pisaturo 1, Laura Occhiello 1, Nicola Coppola 1
 
108.Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139-Ca and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection
 

Hepatol Commun. 2020 Nov 13;5(2):189-202. doi: 10.1002/hep4.1633. eCollection 2021 Feb.

Michel Bazinet 1, Victor Pântea 2, Valentin Cebotarescu 2, Lilia Cojuhari 2, Pavlina Jimbei 3, Mark Anderson 4, Jeff Gersch 4, Vera Holzmayer 4, Carina Elsner 5, Adalbert Krawczyk 5 6, Mary C Kuhns 4, Gavin Cloherty 4, Ulf Dittmer 5, Andrew Vaillant 1
 
109.The changing scenario of hepatitis D
 

J Hepatol. 2021 Jan 20;S0168-8278(21)00023-4. doi: 10.1016/j.jhep.2021.01.014.Online ahead of print.

Mario Rizzetto 1, Saeed Hamid 2, Franco Negro 3
 
110.
 

Oxf Med Case Reports. 2020 Oct 23;2020(10):omaa084.doi: 10.1093/omcr/omaa084. eCollection 2020 Oct.

Meha Bhuva 1, Marie Moore 1, Sambit Sen 1
 
111.New Insights into Hepatitis D Virus Persistence: the Role of Interferon Response and Implications for Upcoming Novel Therapies
 

J Hepatol. 2020 Dec 1;S0168-8278(20)33819-8. doi: 10.1016/j.jhep.2020.11.032.Online ahead of print.

Zhenfeng Zhang 1, Stephan Urban 2
 
112.Virus spread in the liver: mechanisms, commonalities, and unanswered questions
 

Future Virol. 2020 Oct;15(10):707-715. doi: 10.2217/fvl-2020-0158.Epub 2020 Oct 27.

Alexi Tallan 1, Zongdi Feng 1 2
 
113.Residual low HDV viremia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study
 

Liver Int. 2020 Nov 20. doi: 10.1111/liv.14740. Online ahead of print.

Birgit Bremer 1, Olympia Anastasiou 2, Svenja Hardtke 3 4, Florin Alexandru Caruntu 5, Manuela G Curescu 6, Kendal Yalcin 7, Ulus S Akarca 8, Selim Gürel 9, Stefan Zeuzem 10, Andreas Erhardt 11, Stefan Lüth 12, George V Papatheodoridis 13, Monica Radu 5, Ramazan Idilman 14, Michael P Manns 1 4, Markus Cornberg 1 4, Cihan Yurdaydin 14 15, Heiner Wedemeyer 1 4 16
 
114.Hepatitis Delta Virus Epidemiology in the Industrialized World
 

AIDS Rev. 2020 Oct 26;23(3). doi: 10.24875/AIDSRev.20000056. Online ahead of print.

Mehlika Toy 1, Emel Ahishali 2, Cihan Yurdaydin 2
 
115.Risk Factors for Delta Hepatitis in a North American Cohort: Who Should Be Screened?
 

Am J Gastroenterol. 2020 Oct 7. doi: 10.14309/ajg.0000000000000954. Online ahead of print.

Ben L Da 1, Farial Rahman, Walter C Lai, David E Kleiner, Theo Heller, Christopher Koh
 
116.Viral hepatitis and pregnancy
 

Nat Rev Gastroenterol Hepatol. 2020 Oct 12. doi: 10.1038/s41575-020-00361-w.Online ahead of print.

Norah A Terrault 1, Miriam T Levy 2, Ka Wang Cheung 3, Gonzague Jourdain 4 5
 
117.Bulevirtide: First Approval
 

Drugs. 2020 Sep 14.doi: 10.1007/s40265-020-01400-1. Online ahead of print.

Connie Kang 1, Yahiya Y Syed 2
 
118.Hepatitis delta virus propagation enabled by hepatitis C virus - scientifically intriguing; but is it relevant to clinical practice?
 

J Viral Hepat. 2020 Aug 27. doi: 10.1111/jvh.13385. Online ahead of print.

Lisa Sophie Pflüger 1 2, Julian Schulze Zur Wiesch 1 3, Susanne Polywka 2, Marc Lütgehetmann 2 3
 
119.Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta
 

J Viral Hepat. 2020 Jul 24. doi: 10.1111/jvh.13366. Online ahead of print.

Anika Wranke 1, Svenja Hardtke 1 2, Benjamin Heidrich 1 2, George Dalekos 3, Kendal Yalcin 4, Fehmi Tabak 5, Selim Gurel 6, Yilmaz Cakaloglu 7, Ulus S Akarca 8, Frank Lammert 9, Dieter Häussinger 10, Tobias Müller 11, Michael Wöbse 1, Michael P Manns 1 2, Ramazan Idilman 12, Markus Cornberg 1 2, Heiner Wedemeyer 2 13, Cihan Yurdaydin 12 14
 
120.Preliminary evidence for hdv exposure in apparently non-HBV-infected patients
 

Hepatology. 2020 Jul 6. doi: 10.1002/hep.31453. Online ahead of print.

Isabelle Chemin 1, Flor H Pujol 2, Caroline Scholtès 1 3, Carmen L Loureiro 2, Fouzia Amirache 4, Massimo Levrero 1 5, Fabien Zoulim 1 5, Jimena Pérez-Vargas 4, François-Loïc Cosset 4
 
121.Epidemiology, Natural History, and Treatment of Hepatitis Delta Virus Infection in HIV/Hepatitis B Virus Coinfection
 

Curr HIV/AIDS Rep. 2020 Jul 1. doi: 10.1007/s11904-020-00508-z.Online ahead of print.

Nicole D Ferrante 1 2, Vincent Lo Re 3rd 3 4 5
 
122.Infection by Hepatitis Delta Virus
 

Viruses. 2020 Jun 16;12(6):E648. doi: 10.3390/v12060648.

John M Taylor 1
 
123.Hepatitis D Infection: From Initial Discovery to Current Investigational Therapies
 

Gastroenterol Rep (Oxf. 2019 Jun 23;7(4):231-245. doi: 10.1093/gastro/goz023.eCollection 2019 Aug.

Ben L Da 1, Theo Heller 2, Christopher Koh 2
 
124.Current Knowledge on Hepatitis Delta Virus Replication
 

 Antiviarl Res. 2020 Apr 29;179:104812. doi: 10.1016/j.antiviral.2020.104812.Online ahead of print.

Julie Lucifora 1, Marion Delphin 2
 
125.HDVdb: A Comprehensive Hepatitis D Virus Database
 

Viruses. 2020 May 14;12(5):E538.doi: 10.3390/v12050538.

Zainab Usman 1, Stoyan Velkov 2, Ulrike Protzer 2, Michael Roggendorf 2, Dmitrij Frishman 1, Hadi Karimzadeh 2 3
 
126.Hepatitis Delta: Prevalence, Natural History, and Treatment Options
 

Gastroenterol Clin North Am. 2020 Jun;49(2):239-252.doi: 10.1016/j.gtc.2020.01.004.

Julian Hercun 1, Christopher Koh 2, Theo Heller 2
 
127.Current Knowledge on Hepatitis Delta Virus Replication
 

Antiviral Res. 2020 Apr 29;179:104812. doi: 10.1016/j.antiviral.2020.104812.Online ahead of print.

Julie Lucifora 1, Marion Delphin 2
 
128.Migratory Flow and Hepatitis Delta Infection in Italy: A New Challenge at the Beginning of the Third Millennium
 

 Viral Hepat. 2020 Apr 27. doi: 10.1111/jvh.13310. Online ahead of print.

Tommaso Stroffolini 1, Alessia Ciancio 2, Caterina Furlan 1, Maria Vinci 3, Rosanna Fontana 4, Maurizio Russello 5, Guido Colloredo 6, Filomena Morisco 7, Nicola Coppola 8 9, Sergio Babudieri 10, Luigina Ferrigno 11, Caterina Sagnelli 9, Evangelista Sagnelli 9
 
129.The Global Prevalence of Hepatitis D Virus Infection: Systematic Review and Meta-Analysis
 

J Hepatol. 2020 Apr 23;S0168-8278(20)30220-8. doi: 10.1016/j.jhep.2020.04.008.Online ahead of print.

Alexander J Stockdale 1, Benno Kreuels 2, Marc Y R Henrion 3, Emanuele Giorgi 4, Irene Kyomuhangi 4, Catherine de Martel 5, Yvan Hutin 6, Anna Maria Geretti 7
 
130.Management of Viral Hepatitis A, C, D and E in Pregnancy
 

Best Pract Res Clin Obstet Gynaecol 2020 Mar 21;S1521-6934(20)30050-X.

doi: 10.1016/j.bpobgyn.2020.03.009. Online ahead of print.

Mimi Tin-Yan Seto 1, Ka Wang Cheung 2, Ivan F N Hung 3
 
131.Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies
 

Alfaiate D1, Clément S2, Gomes D1, Goossens N3, Negro F4. J Hepatol. 2020 Mar 6. pii: S0168-8278(20)30129-X. doi: 10.1016/j.jhep.2020.02.030. [Epub ahead of print]
 
132.Long-term study of hepatitis D infection at secondary care centers: the impact of viremia on liver-related outcomes
 

Kamal H1,2, Westman G3, Falconer K1,2, Duberg AS4, Weiland O1,2, Haverinen S1, Wejstål R5, Carlsson T6, Kampmann C7, Larsson S8, Björkman P9, Nystedt A10, Cardell K10, Svensson S11, Stenmark S12, Wedemeyer H13, Aleman S1,2. Hepatology. 2020 Mar 7. doi: 10.1002/hep.31214. [Epub ahead of print]
 
133.Chronic Viral Hepatitis: Current Management and Future Directions
 

Do A1, Reau NS2. Hepatol Commun. 2020 Jan 20;4(3):329-341. doi: 10.1002/hep4.1480. eCollection 2020 Mar
 
134.Treatment of hepatitis D, an unmet medical need
 

Caviglia GP1, Rizzetto M2. Clin Microbiol Infect. 2020 Feb 28. pii: S1198-743X(20)30135-X. doi: 10.1016/j.cmi.2020.02.031.

 
135.Future treatments for hepatitis delta virus infection
 

Asselah T1,2, Loureiro D1,2, Tout I1,2, Castelnau C1,2, Boyer N1,2, Marcellin P1,2, Mansouri A1,2. Liver Int. 2020 Feb;40 Suppl 1:54-60. doi: 10.1111/liv.14356.
 
136.New epidemiology of hepatitis delta
 

Vlachogiannakos J1, Papatheodoridis GV1. Liver Int. 2020 Feb;40 Suppl 1:48-53. doi: 10.1111/liv.14357.
 
137.The oncogenic role of hepatitis delta virus in hepatocellular carcinoma
 

Puigvehí M1,2, Moctezuma-Velázquez C1, Villanueva A1,3,4, Llovet JM1,5,6,4. JHEP Rep. 2019 May 16;1(2):120-130. doi: 10.1016/j.jhepr.2019.05.001. eCollection 2019 Aug.
 
138.Hepatitis delta genotype 5 is associated with favourable disease outcome and better response to treatment compared to genotype 1
 

Spaan M1, Carey I2, Bruce M2, Shang D2, Horner M2, Dusheiko G2, Agarwal K2. J Hepatol. 2020 Jan 22. pii: S0168-8278(20)30023-4. doi: 10.1016/j.jhep.2019.12.028. [Epub ahead of print]
 
139.High rates of cirrhosis and severe clinical events in patients with HBV/HDV co-infection: longitudinal analysis of a German cohort
 

Bockmann JH1,2, Grube M3, Hamed V3, von Felden J3, Landahl J3, Wehmeyer M3, Giersch K3, Hall MT4,5, Murray JM4,5, Dandri M3,6, Lüth S3,7, Lohse AW3,6, Lütgehetmann M3,8, Schulze Zur Wiesch J3,6. BMC Gastroenterol. 2020 Jan 30;20(1):24. doi: 10.1186/s12876-020-1168-9.
 
140.Spontaneous clearance of chronic delta hepatitis
 

Kapuria D1,2, Ben Yakov G1, Koh C1, Heller T1. Hepatology. 2019 Dec 23. doi: 10.1002/hep.31073. [Epub ahead of print]
 
141.Economic and Healthcare Burdens of Hepatitis Delta: A Study of Commercially Insured Adults in the United States
 

Elsaid MI1, Li Y1, John T1, Narayanan N2,3, Catalano C1, Rustgi VK1. Hepatology. 2019 Dec 5. doi: 10.1002/hep.31055. [Epub ahead of print]
 
142.Estimating the global prevalence, disease progression and clinical outcome of hepatitis delta virus infection
 

Miao Z1, Zhang S1, Ou X1, Li S1,2, Ma Z3, Wang W1,4, Peppelenbosch MP1, Liu J1, Pan Q1. J Infect Dis. 2019 Nov 28. pii: jiz633. doi: 10.1093/infdis/jiz633. [Epub ahead of print]
 
143.HBV/HDV Coinfection: A Challenge for Therapeutics
 

Koh C1, Da BL2, Glenn JS3. Clin Liver Dis. 2019 Aug;23(3):557-572. doi: 10.1016/j.cld.2019.04.005. Epub 2019 May 24.
 
144.HDV infection in immigrant populations
 

Coppola N1,2, Alessio L2, Onorato L1, Sagnelli C1,2, Sagnelli E1, Pisaturo M1. J Med Virol. 2019 Dec;91(12):2049-2058. doi: 10.1002/jmv.25570. Epub 2019 Aug 27.
 
145.Chronic hepatitis delta: A state-of-the-art review and new therapies
 

Gilman C1, Heller T1, Koh C2. World J Gastroenterol. 2019 Aug 28;25(32):4580-4597. doi: 10.3748/wjg.v25.i32.4580.
 
146.Master of disguise: hepatitis delta virus packaging and spread facilitated by diverse viral envelope proteins
 

Maya S1, Ploss A1. Hepatology. 2019 Aug 29. doi: 10.1002/hep.30922. [Epub ahead of print]
 
147.Recurrence of Hepatitis D Virus in Liver Transplant Recipients With Hepatitis B and D Virus-Related Chronic Liver Disease
 

Serin A, Tokat Y. Transplant Proc. 2019 Sep;51(7):2457-2460. doi: 10.1016/j.transproceed.2019.01.163. Epub 2019 Aug 9.
 
148.We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade
 

Lazarus JV1, Pericàs JM2, Picchio C1, Cernosa J3, Hoekstra M1, Luhmann N4, Maticic M5,6, Read P7, Robinson EM8, Dillon JF8. J Intern Med. 2019 Aug 31. doi: 10.1111/joim.12972. [Epub ahead of print]
 
149.Effectiveness of Noninvasive Fibrosis Markers for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B and Chronic Hepatitis B+D Induced Cirrhosis
 

Sahin T, Serin A, Emek E, Bozkurt B, Arikan BT, Tokat Y. Transplant Proc. 2019 Aug 8. pii: S0041-1345(18)31711-1. doi: 10.1016/j.transproceed.2019.01.193. [Epub ahead of print
 
150.A review on hepatitis D: From virology to new therapies
 

Mentha N1, Clément S2, Negro F2,3, Alfaiate D1. J Adv Res. 2019 Mar 29;17:3-15. doi: 10.1016/j.jare.2019.03.009. eCollection 2019 May.
 
151.Novel hepatitis D-like agents in vertebrates and invertebrates
 

Chang WS1, Pettersson JH1,2, Le Lay C1, Shi M1, Lo N1, Wille M3, Eden JS1,4, Holmes EC1. Virus Evol. 2019 Jul 15;5(2):vez021. doi: 10.1093/ve/vez021. eCollection 2019 Jul.
 
152.Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial
 

Wedemeyer H1, Yurdaydin C2, Hardtke S3, Caruntu FA4, Curescu MG5, Yalcin K6, Akarca US7, Gürel S8, Zeuzem S9, Erhardt A10, Lüth S11, Papatheodoridis GV12, Keskin O13, Port K14, Radu M4, Celen MK6, Idilman R13, Weber K15, Stift J16, Wittkop U17, Heidrich B3, Mederacke I14, von der Leyen H18, Dienes HP16, Cornberg M14, Koch A15, Manns MP19; HIDIT-II study team. Lancet Infect Dis. 2019 Mar;19(3):275-286. doi: 10.1016/S1473-3099(18)30663-7.
 
153.Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy
 

Yurdaydin C1, Abbas Z2, Buti M3, Cornberg M4, Esteban R3, Etzion O5, Gane EJ6, Gish RG7, Glenn JS7, Hamid S8, Heller T9, Koh C9, Lampertico P10, Lurie Y11, Manns M4, Parana R12, Rizzetto M13, Urban S14, Wedemeyer H15; Hepatitis Delta International Network (HDIN). J Hepatol. 2019 May;70(5):1008-1015. doi: 10.1016/j.jhep.2018.12.022. Epub 2018 Dec 27.
 
154.Chronic hepatitis delta virus infection leads to functional impairment and severe loss of MAIT cells
 

Dias J1, Hengst J2, Parrot T1, Leeansyah E3, Lunemann S4, Malone DFG1, Hardtke S5, Strauss O1, Zimmer CL1, Berglin L1, Schirdewahn T5, Ciesek S6, Marquardt N1, von Hahn T5, Manns MP5, Cornberg M5, Ljunggren HG1, Wedemeyer H7, Sandberg JK1, Björkström NK8. J Hepatol. 2019 Aug;71(2):301-312. doi: 10.1016/j.jhep.2019.04.009. Epub 2019 May 14.
 
155.HBV/HDV Coinfection: A Challenge for Therapeutics
 

Koh C1, Da BL2, Glenn JS3. Clin Liver Dis. 2019 Aug;23(3):557-572. doi: 10.1016/j.cld.2019.04.005. Epub 2019 May 24.
 
 
 

HEPATITIS

HBV
HCV
HDV

CLD HEALTH OUTCOMES

CIRRHOSIS

Cirrhosis
HE
HRS
Thrombocytopenia

NASH

Slide Library
Publications
Webcasts
Abstract Library Committee Members

CHOLESTATIC

PBC

HCC

Slide Library
Publications
Webcasts
Algorithm
Abstract Library Committee Members

ALCOHOL LIVER DISEASE

Recorded Educational Webinar

PEDIATRIC LIVER DISEASE

Webcasts
Slide Library
Abstract Library

About CLDF

Board of Trustees
Board of Advisors/Faculty
CLDF Committees
2023 GI Fellow Board of Advisors

Other Resources

Journal Abstracts
Hep C Link to Care

Subscribe

Be the first to know about our latest upcoming programs and events!
CLDF

Follow us
Facebook
Twitter
Youtube
LiverQ
The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2023 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.